Tregs, in a CTLA-4-dependent manner, inhibit proliferation of CD4+ and CD8+ T cells and downregulate the expression of co-stimulatory molecules (CD80 and CD86) on DCs, attenuating their capacity for induction of effective anti-tumour immunity [67]. This evidence concerns the gene CD4 and neoplasm.